IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Breast Cancer|Squamous Cell Cancer of Head and Neck|Colorectal Cancer
Interventions: DRUG: IMM2520
Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Collaborators: Shandong Cancer Hospital and Institute